COMPASS Pathways PLC (CMPS)
| Market Cap | 1.38B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -65.74M |
| Shares Out | 41.70M |
| EPS (ttm) | -2.10 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 161,220 |
| Open | 32.28 |
| Previous Close | 32.62 |
| Day's Range | 31.90 - 33.10 |
| 52-Week Range | 29.31 - 61.69 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 72.11 (+123.6%) |
| Est. Earnings Date | Nov 11, 2021 |
About CMPS
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for CMPS stock is "Strong Buy." The 12-month stock price forecast is 72.11, which is an increase of 123.60% from the latest price.
News
1 Recent Healthcare IPO to Put on Your Radar
Here's a pharmaceutical company that could have an incredibly bright future.
COMPASS Pathways to participate in upcoming Maxim and Cantor investor conferences
London, UK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, a...
Is the Options Market Predicting a Spike in COMPASS Pathways (CMPS) Stock?
Investors need to pay close attention to COMPASS Pathways (CMPS) stock based on the movements in the options market lately.
Compass: Psychedelics Unicorn Expands Portfolio Beyond Psilocybin Into Psychedelics 2.0
Psychedelics biotech company Compass Pathways (NASDAQ:CMPS) has purchased an intellectual property portfolio that includes patent applications for a variety of psychedelic and empathogenic substances. C...
COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it has acquired an in...
Hamilton Morris joins COMPASS Pathways to research new psychedelic compounds
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has engaged Hamilton Morris, the res...
COMPASS Pathways to participate in Citi, Morgan Stanley and HC Wainwright investor conferences in September
London, UK – 7 September 2021, Sept. 07, 2021 (GLOBE NEWSWIRE) -- London, UK – 7 September 2021 COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating pati...
3 Biotech Stocks Wall Street Expects to Double Soon
All three stocks on this list can more than double your money according to investment bank analysts who cover them.
Open-Minded? Buy This Game-Changing Psychedelics Stock Now
Excellent investing opportunities frequently seem outlandish.
Are Options Traders Betting on a Big Move in COMPASS Pathways (CMPS) Stock?
Investors need to pay close attention to COMPASS Pathways (CMPS) stock based on the movements in the options market lately.
3 Disruptive Mental Health Stocks to Consider Buying Before They're Huge
They're the first pioneers in exciting new markets.
COMPASS Pathways plc announces financial results and business highlights for the second quarter 2021
LONDON, Aug. 11, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today ...
Growing Psychedelic Interest Will Help Push Compass Pathways Stock Up 3X By 2022
By 2030, psychedelic therapy will be the gold standard for mental health treatment. And Compass is at the forefront of commercialization.
COMPASS Pathways plc to announce second quarter 2021 financial results on 11 August 2021
London, UK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, an...
COMPASS Pathways to Participate in BTIG and Canaccord Genuity Investor Conferences
COMPASS Pathways to Participate in BTIG and Canaccord Genuity Investor Conferences COMPASS Pathways to Participate in BTIG and Canaccord Genuity Investor Conferences
7 Stocks to Buy if You Think Alternative Therapies Are the Future
Here are seven stocks to buy if you're optimistic about the potential for alternative therapies to become mainstream treatments. The post 7 Stocks to Buy if You Think Alternative Therapies Are the Futur...
Danielle Schlosser joins COMPASS Pathways from Verily Life Sciences to lead clinical innovation and therapist training
London, UK – 21 July 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, an...
Is It Too Early to Invest in Psychedelic Stocks?
Legislation is starting to open up the industry but investors who are hoping to cash in on its growth opportunities could be waiting a very long time.
COMPASS Pathways to participate in Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit
London, UK, July 07, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, an...
COMPASS Pathways joins forces with King's College London and South London and Maudsley NHS Foundation Trust to accele...
London, UK – 5 July 2021
3 Top Psychedelic Stocks to Buy Now
These companies developing hallucinogens have more than meets the eye.
COMPASS Pathways launches new podcast “Everyone has a story: talking about mental health”
London, UK – 30 June 2021
Compass Pathways Completes Target Administration Of Psilocybin Therapy In World's Largest Study
Compass Pathways (NASDAQ:CMPS), a biotech company in the psychedelics space, announced it has completed a key milestone on its path to obtaining FDA approval for psilocybin in the treatment of depressio...
Pandemic Fallout: 6 Mental Health Stocks To Watch
One of the most devastating long-term impacts of the COVID-19 pandemic may be the toll it has taken on people's mental health. The next global health crisis may be related to mental health issues such a...
COMPASS Pathways completes COMP360 psilocybin therapy administration for 216 patients in large-scale phase IIb psiloc...
COMPASS on track to report data in late 2021 COMPASS on track to report data in late 2021